These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 1356869)

  • 21. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus.
    Koek GH; Sifrim D; Lerut T; Janssens J; Tack J
    Gut; 2008 Aug; 57(8):1056-64. PubMed ID: 18403496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy for chronic gastro-oesophageal reflux disease and Barrett's oesophagus.
    Wurm P; de Caestecker J
    Expert Opin Pharmacother; 2003 Jul; 4(7):1049-61. PubMed ID: 12831333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the magnitude of gastro-oesophageal reflux in Barrett's oesophagus.
    Parrilla P; Ortiz A; Martinez de Haro LF; Aguayo JL; Ramirez P
    Gut; 1990 Sep; 31(9):964-7. PubMed ID: 2210462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent gastric acid inhibition in the management of Barrett's oesophagus.
    Lanas A
    Drugs; 2005; 65 Suppl 1():75-82. PubMed ID: 16335861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Barrett's oesophagus: optimal strategies for prevention and treatment.
    Fass R; Sampliner RE
    Drugs; 2003; 63(6):555-64. PubMed ID: 12656653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.
    Eusebi LH; Telese A; Cirota GG; Haidry R; Zagari RM; Bazzoli F; Ford AC
    Aliment Pharmacol Ther; 2021 May; 53(9):968-976. PubMed ID: 33705573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of intragastric and intraoesophageal alkalinisation in the genesis of complications in Barrett's columnar lined lower oesophagus.
    Attwood SE; Ball CS; Barlow AP; Jenkinson L; Norris TL; Watson A
    Gut; 1993 Jan; 34(1):11-5. PubMed ID: 8432439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity.
    Nehra D; Howell P; Williams CP; Pye JK; Beynon J
    Gut; 1999 May; 44(5):598-602. PubMed ID: 10205192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of omeprazole or anti-reflux surgery on lower oesophageal sphincter characteristics and oesophageal acid exposure over 10 years.
    Emken BG; Lundell LR; Wallin L; Myrvold HE; Engström C; Montgomery M; Malm AR; Lind T; Hatlebakk JG;
    Scand J Gastroenterol; 2017 Jan; 52(1):11-17. PubMed ID: 27593706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of cisapride on oesophageal motility and duodenogastro-oesophageal reflux in patients with Barrett's oesophagus.
    Smythe A; Bird NC; Troy GP; Globe J; Johnson AG
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1149-53. PubMed ID: 9471019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acid suppression and surgical therapy for Barrett's oesophagus.
    de Jonge PJ; Spaander MC; Bruno MJ; Kuipers EJ
    Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):139-50. PubMed ID: 25743462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Barrett's oesophagus: pH profile.
    Gillen P; Keeling P; Byrne PJ; Hennessy TP
    Br J Surg; 1987 Sep; 74(9):774-6. PubMed ID: 3664238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of acid and bile reflux in oesophagitis and Barrett's metaplasia.
    Souza RF
    Biochem Soc Trans; 2010 Apr; 38(2):348-52. PubMed ID: 20298181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Sep; 38(9):643-8. PubMed ID: 16627016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications.
    Ladanchuk TC; Johnston BT; Murray LJ; Anderson LA;
    Scand J Gastroenterol; 2010 Dec; 45(12):1397-403. PubMed ID: 20626305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
    Menges M; Müller M; Zeitz M
    Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
    Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
    Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathophysiological characteristics of long- and short-segment Barrett's oesophagus.
    Zentilin P; Reglioni S; Savarino V
    Scand J Gastroenterol Suppl; 2003; (239):40-3. PubMed ID: 14743882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.